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Computational analysis of 
the evolutionarily conserved 
Missing In Metastasis/Metastasis 
Suppressor 1 gene predicts novel 
interactions, regulatory regions 
and transcriptional control
petar petrov  1, Alexey V. sarapulov  1, Lel eöry2, Cristina scielzo  3,4, Lydia scarfò  3,4,5, 
Jacqueline smith  2, David W. Burt  6 & pieta K. Mattila  1
Missing in Metastasis (MIM), or Metastasis Suppressor 1 (MTSS1), is a highly conserved protein, 
which links the plasma membrane to the actin cytoskeleton. MIM has been implicated in various 
cancers, however, its modes of action remain largely enigmatic. Here, we performed an extensive in 
silico characterisation of MIM to gain better understanding of its function. We detected previously 
unappreciated functional motifs including adaptor protein (Ap) complex interaction site and a C-helix, 
pointing to a role in endocytosis and regulation of actin dynamics, respectively. We also identified 
new functional regions, characterised with phosphorylation sites or distinct hydrophilic properties. 
strong negative selection during evolution, yielding high conservation of MIM, has been combined 
with positive selection at key sites. Interestingly, our analysis of intra-molecular co-evolution revealed 
potential regulatory hotspots that coincided with reduced potentially pathogenic polymorphisms. 
We explored databases for the mutations and expression levels of MIM in cancer. experimentally, we 
focused on chronic lymphocytic leukaemia (CLL), where MIM showed high overall expression, however, 
downregulation on poor prognosis samples. Finally, we propose strong conservation of MTSS1 also 
on the transcriptional level and predict novel transcriptional regulators. our data highlight important 
targets for future studies on the role of MIM in different tissues and cancers.
Missing In Metastasis (MIM), or Metastasis Suppressor 1 (MTSS1) is a protein linked to various cancers, inter-
estingly, either as a putative tumour metastasis suppressor, or promoting factor1. Since its identification in 2002 
as a metastasis suppressor in bladder cancer2, MIM has been a target of several studies and has been linked to 
a multitude of cellular partners. MIM possesses a characteristic inverse Bin, Amphiphysin, Rvs I-BAR (I-BAR, 
or IRSp53, MIM (IM)) domain, which binds and deforms cellular membranes and promotes cell protrusion 
formation3,4. It can also directly interact with actin, via its C-terminal WH2 domain (Wiskott-Aldrich syn-
drome homology region 2)5 and with multiple actin cytoskeleton regulatory proteins, such as cortactin and Rac1 
GTPase3,6,7. These activities place MIM at the interface of the plasma membrane and cellular cytoskeleton, the two 
structures that play a critical role in determining cell morphology, cellular interactions and mechanics.
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The I-BAR domain family in vertebrates consists of 5 proteins, MIM, ABBA (or MTSS1L), insulin recep-
tor tyrosine kinase substrate p53 (IRSp53 or BAIAP2), insulin receptor tyrosine kinase substrate (IRTKS or 
BAIAP2L1) and Pinkbar (or FLJ22582 or BAIAP2L2)8. In this family, MIM and IRSp53 form two sub-branches 
and also show highest conservation, with divergent orthologues found from human to the fruit fly. In amoeba and 
fungi, there is a single ancestral I-BAR domain protein9,10.
There is a wealth of literature characterising MIM with reduced expression in metastasis or primary tumours 
of, for example, bladder, breast, gastric, kidney, prostate cancers, and acute lymphoblastic leukemia of B cell 
origin1,11–17. The expression of MTSS1 can be regulated at multiple levels as illustrated by the regulation by DNA 
methylation18–21 and microRNAs22. Interestingly, however, while most literature consider MIM as a metastasis or 
tumour suppressor, at the same time, upregulation of MIM in hepatocellular and head and neck squamous cell 
carcinomas, as well as correlation of overexpression of MIM and poor prognosis in colorectal cancer has been 
reported23–25.
Despite the association with various cancers, high conservation and multiple activities of MIM, the physio-
logical role of the protein has been difficult to determine. The knockout mouse for MIM is viable without gross 
abnormalities, however, these mice have been reported to develop kidney failure and lymphoma, as well as show-
ing defective neuronal synapse formation and bone marrow cell trafficking17,26–28. Despite the knockout studies 
and many cellular and biochemical studies, there still remains a major gap in our understanding of how this 
highly conserved protein functions in vivo and how it affects cancer. In silico analyses of proteins and their genes 
can highlight new features and functions that could otherwise go unappreciated. Computational phylogenetic 
analyses represent a powerful tool to study the evolution of genes and their encoded proteins. Tests for evolu-
tionary pressure allow estimation of the type and extent of natural selection for branches and individual sites. 
Negative (purifying) selection, acting to eliminate unfavourable and deleterious mutations, is the predominant 
type of selection observed for genes29. Houskeeping and essential genes frequently evolve under strong negative 
selection30 leading to high sequence conservation. The much more rare, positive (Darwinian) selection, promotes 
molecular adaptation by favouring mutations providing advantage to the organism. Positive selection has been 
frequently described for genes involved in immunity, reproduction and sensory systems31. Transcriptional reg-
ulation of gene expression and its changes in respect to phylogeny, is an appealing, but rather complex aspect of 
the evolution of genes. Nucleotide substitutions within the transcription factor binding site (TFBS) are likely to 
affect the binding affinity and thereby expression levels of the gene32 and it has been shown that promoter regions 
of genes have high turnover rate33. In the course of evolution, such changes can lead to phenotypic differences and 
speciation34 and their identification can unveil a species-specific transcriptional regulation of the gene. However, 
due to the short length and highly degenerative nature of transcription factor binding sites35, their identification 
represents a challenge. The expression of MIM is known to be tissue-specific and is particularly highly expressed, 
for example, in B lymphocytes of the adaptive immune system17,36.
Here, we present the evolution of the MIM protein and its domain structure within vertebrates, by extensive 
in silico characterisation of the protein and its gene MTSS1. Our analyses identified new, previously unchar-
acterised regions and motifs in the MIM protein, including several AP interaction sites suggestive of a role in 
endocytosis and a potential actin regulatory motif C-helix. Analysis of intra-molecular co-evolution revealed 
inter-dependency between different parts of MIM, which also showed notably low rate of potentially pathogenic 
polymorphisms, proposing them as important regulatory regions. Towards the role of MIM in human disease, 
we report alterations and specific mutations of MIM in multiple cancers. Chronic lymphocytic leukaemia (CLL) 
is the most frequent adult leukaemia in Western countries and is characterised by the expansion of monoclonal 
CD5+ B lymphocytes that accumulate and traffic between the Peripheral Blood (PB), Bone Marrow (BM) and 
secondary lymphoid organs37,38. The clinical course of CLL is very heterogeneous: the majority of patients have an 
indolent clinical course with no treatment need and with long survival, while others experience aggressive disease 
requiring early treatment followed by frequent relapses39. Here, we experimentally characterise the expression 
levels of MTSS1 in CLL and show an interesting heterogeneous expression pattern in different stages of cancer. 
Finally, to bring new understanding to the regulation of MTSS1 gene expression, highly significant both in cancer 
and in the tissue-specific physiological functions, we illustrate evolutionarily conserved transcriptional regulation 
with prediction of new transcription factor binding sites. Taken together, our work exemplifies a detailed in silico 
characterisation of MIM, which leads to identification of new potential functional motifs and proposal of impor-
tant regulatory regions and amino acids selected in evolution. We also bring new insights into the behaviour of 
MIM in cancers as well as its transcriptional regulation.
Results
Analysis of MIM sequence and its orthologues suggests new motifs and functional features. 
Aiming to identify new functional features of MIM, we conducted a thorough characterisation of its protein 
sequence and investigated the evolution of its gene. The gene encoding the MIM protein is called MTSS1 and is 
found on chromosome 8 in human and chromosome 15 in mouse. Its longest isoform in these species is coded 
by transcript variant 1, which is the transcript variant used in this study (hereafter referred to as “MIM” for the 
protein and “MTSS1” for the gene).
To characterise the domain structure of MIM in human and mouse in high detail, we conducted extensive pre-
dictions of its protein topology (Fig. 1a). As reported earlier, MIM is a 759 amino acids long cytoplasmic protein 
with a large, N-terminal, membrane binding and deforming I-BAR domain, and a small C-terminal actin-binding 
WH2 domain. The I-BAR domain is followed by a long Ser-rich region, while a Pro-rich region, of relatively 
equal size, precedes the WH2 domain. Here, we observed a small, highly hydrophilic region in the centre of the 
polypeptide chain, with relatively short Ser/Thr-rich regions and a Leu-rich region residing C-terminal from it. 
Interestingly, one Ser- and two Tyr- phosphorylation sites, S326 and Y397/398, that have been experimentally 
determined40,41, reside within this Ser-rich region. The IUPred2A server42, on the other hand, predicted several 
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Figure 1. The conserved protein topology of MIM suggests various functional motifs and regions. (a) Protein 
topology of MIM (H. sapiens). Names of domains, regions and motifs that have been reported previously are 
indicated in colour, while those identified in this study are indicated in black. Domains: I-BAR (Inverse Bin, 
Amphiphysin, Rvs), WH2 (WH2: Wiskott-Aldrich syndrome homology region 2); regions: SR (serine rich), S/
TR (serine/threonine rich), hyphil (hydrophilic), LR (leucine rich), TR (threonine rich), PR (proline rich), DBR 
(intrinsically disordered binding region). Motifs: NLS (nuclear localisation signal), AP2α-int (Adaptor Protein 
2 α-subunit interacting), APµ-int (Adaptor Protein µ-subunit interacting), C-helix (central helix), LIR (LC3-
interacting), NES (nuclear export signal), SH3-int (SH3 domain interacting motif). Other: +++ (a patch of 
basic residues), S326 (serine phosphorylation target), Y397 and Y398 (tyrosine phosphorylation targets). (b) 
Comparison of C-helix from MIM in human with C-helices from other proteins. The corresponding regions in H. 
sapiens (Hs) and M. musculus (Mm) are aligned for MIM, WASP, N-WASP, NCK1, NCK2 and WASH. Motifs are 
enclosed in red. Amino acid positions correspond to MIM from H. sapiens. Hydrophobic residues at positions 
+1, +5 and +9 are pointed by arrows. The motif is not detected by ELM in mouse, due to a T at position +2. (c) 
Protein topology of MIM in other species. Representative species from: mammals (M. musculus), birds (G. gallus), 
reptiles (A. carolinensis) and fish (L. oculatus). (d) Conservation of the I-BAR domain from MIM. I-BAR dimer is 
shown with conservation plotted on chain A, while chain B is shown in gold. Level of conservation is depicted 
in a magenta (conserved) to cyan (variable) gradient. A rotated (Y-axis, 270°) view of the dimer is shown to the 
right. The most prominent variable region involves four residues encoded by exon 7 in MTSS1 transcript variant 1 
and is located at the tip of the elongated dimer structure. Areas of interest, where APµ-int/LIR and AP2α-int/LIR 
motifs were detected are enclosed by a green and an orange frame, respectively. (e) Structural properties of APµ-int/
LIR and AP2α-int/LIR motifs area. Left (green frames): overlapping motifs LIR (DKYLLL) and APµ-int (YLLL); 
right (orange frames): partly overlapping motifs AP2α-int (FLDAF) and LIR (DAFQKV). Motif area depicts the 
protein surface area occupied by the motif residues (sequence is colour-coded in the bottom). Ribbon & atoms 
shows the position of the motif residues and their side-chains on the structure ribbon view, observed through a 
semi-transparent surface. The surface hydrophobicity and electrostatic potential are indicated. The APµ-int region 
shows high hydrophobicity and predominantly negative electrostatic potential.
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disordered binding regions (DBR): a small one spanning through the short central Ser/Thr-rich regions, and a 
large DBR that covers most of the Pro-rich region and the WH2 domain. Numerous short functional motifs are 
found over MIM, some of which have been reported earlier1,43, while others were identified in our study. The 
I-BAR domain contains nuclear-localisation signals (NLS) with a nested patch of basic amino acids and a nuclear 
export signal (NES), while a second NES has been reported for the small Leu-rich region. The Pro-rich region is 
abundant in SH3-interacting (SH3-int) motifs containing the majority of such motifs that are found in MIM43.
Our analysis, carried out using the Eukaryotic Linear Motif (ELM)44 resource, revealed various new motifs 
and features (Fig. 1a). In the I-BAR domain, the analysis predicted interacting motifs for the α- and µ- subunits 
of the Adaptor Protein complex (AP2α-int and APµ-int), involved in clathrin-mediated endocytosis45. Each of 
them overlaps with an LC3-interacting (LIR) motif for binding to ATG8 proteins, implicated in autophagy46. The 
overlapping motifs are referred later as AP2α-int/LIR and APµ-int/LIR to denote their common location. In the 
Leu-rich region, we predicted an amphipathic α-helix motif, called Central helix motif (C-helix), characterised as 
a ligand for GTPase-binding domain of WASP and N-WASP (Fig. 1b, see below). Down from the Leu-rich region, 
where no particular domains are identified, we found three additional APµ-int motifs, two of which overlay with 
each other. In addition, we found multiple other previously unreported functional motifs associated with kinases, 
proteases and several protein modifiers, which suggest tight regulatory control of MIM protein stability and pro-
vide clues towards possible functions. A full list of conserved functional motifs identified in our searches can be 
found in Supplementary Table S1.
We also characterised MIM from representative species from birds, reptiles and fish: chicken (Gallus gallus), 
lizard (Anolis carolinensis) and black-spotted gar (Lepisosteus oculatus), respectively (Fig. 1c). The overall pro-
tein topology of MIM in these species is very similar to that in human and mouse, underlining a high degree of 
conservation. Minor differences were observed in the proportion of Ser/Thr residues proximal to the hydrophilic 
region and the distribution of the SH3int motifs within the Pro-rich regions. A small Ser-rich region nested 
within the Pro-rich region was found in lizard, while black-spotted gar had only one of the tyrosines shown to be 
phosphorylated in mouse.
Considering the high degree of conservation of the I-BAR domain, we generated a structure conservation 
plot47 (Fig. 1d) based on all orthologous sequences (Supplementary Table S2, Fig. 2) used in this study. The crystal 
structure of the domain is available from mouse48 and its sequence has a 98.9% overall identity to the I-BAR from 
human MIM. As illustrated by the analysis, the domain has remained extremely conserved, with only a few areas 
showing higher variability. A prominent highly variable region, composed of four amino acids (residues 154–157) 
was detected at each tip of the elongated I-BAR dimer, connecting two of the α-helices. This peculiar region is 
encoded by a short exon of only these four amino acids (exon 7), which is alternatively spliced in isoform 2 of 
human MTSS1 transcript. Several moderately variable amino acid regions were detected in the central part of the 
domain and in the NES motif. However, none of these residues was detected to be under positive selection in our 
subsequent analyses (see next section).
Intrigued by the suggested AP2α-int, APµ-int and LIR motifs within the I-BAR, that emerged from our analy-
sis, we investigated their structural positioning (Fig. 1d,e). We observed that the surface of the APµ-int/LIR motif 
stands out as an area of higher hydrophobicity, adjacent to a groove of negative electrostatic potential, according 
to Coulombic surface colouring. These features fit well for a protein-protein interaction site. For the AP2α-int/
LIR motif, however, the surface hydrophobicity and electrostatic potential did not reveal deviation from the sur-
rounding molecule surface. Moreover, the first two residues of the AP2α-int motif have their side chains buried 
into the core of the structure, not contributing to the surface area. Based on this, the APµ-int/LIR motif emanates 
as a promising candidate for a novel interaction of MIM, while AP2α-int/LIR motif appears significantly less 
exposed for potential interaction. Another interesting finding, considering the long-known role of MIM as an 
actin regulatory protein, is the prediction of the C-helix, which is present in the VCA domains of, for exam-
ple, WASP and N-WASP, actin nucleation promoting factors regulating Arp2/3-mediated actin polymerization49 
(Fig. 1b). Indeed, sequence alignment of the C-helix peptides from several actin regulatory proteins show high 
degree of conservation at hydrophobic amino acids at positions +1, +5 and +9, the main contributing residues 
responsible for interaction with GTPase-binding domain, Arp2/3 and/or monomeric actin50,51.
These potential new structural features reinforce the view that MIM is a multifunctional protein with many 
interaction partners, at the same time suggesting new functions in endocytosis and/or autophagy and actin 
dynamics.
MIM has been subjected to an overall negative selection with positive selection at key sites. 
To evaluate the importance of these features as well as the overall conservation of MIM in vertebrates, we ana-
lysed the evolutionary relations of its orthologues. To this end, we executed a series of homology searches against 
the publicly available databases at NCBI and identified orthologous sequences from a total of 52 mammals, 24 
birds, 10 reptiles and 8 fish (Supplementary Table S2, see “Materials and Methods” for details). For our phyloge-
netic analyses, including phylogeny-aware sequence alignments performed by PRANK52, we obtained species 
trees from the TimeTree53 public knowledge-base. We employed the ModelFree branch method implemented in 
CodeML from PAML54 to determine the ω-values and branch lengths in the phylogenetic tree, covering all species 
analysed (Fig. 2 and Supplementary Table S3). Again, denoting the high conservation of MIM, the overall values 
of ω were distinctly low (typically ω < 0.1, with highest ω ~ 0.6), suggesting that negative selection has operated 
across branches. Slightly increased ω values were detected among fish, some reptiles and birds. Towards H. sapi-
ens, several higher values were observed, as well as among apes. Branch lengths were shortest among hominids 
and Old World monkeys and longest in fish and some reptiles.
To expand our understanding about the critical features of MIM, we decided to investigate the molecular 
evolution of its gene, MTSS1. In general, proteins with stringent functional or structural requirements are marked 
with a strong negative (purifying) selection, resulting in few amino acid changes through their evolution55. To 
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gain an understanding of the selection that has operated on the MTSS1 gene, we used computational meth-
ods employing complementary models of selection. We focused on MTSS1 in mammals and tested its coding 
sequence for signs of negative and positive (pervasive or episodic, selected sites in bold or cursive, respectively) 
selection. We used CodeML from the PAML suite with site Model 8 (M8), together with SLAC56, FUBAR57 and 
MEME58 from HyPhy59 (see “Materials and Methods” and Supplementary Tables S4–S8 for details, including 
rejection of the null hypothesis by CodeML). By combining the results, we could verify that MTSS1 had been sub-
jected to a broad, negative purifying selection, with positive selection occurring at individual sites (Fig. 3a). Most 
of the positively selected sites were detected in the central section of the molecule: three in the Ser-rich region 
(Y357, T368, A395), and three in the neighbouring Ser/Thr minor regions (T447, A449, T471). At the opposite 
end of MIM, two sites (Q715 and I716) within the Pro-rich region, were found to be positively selected.
We tracked the amino acid changes that have occurred across the mammalian tree for each selected site. 
Reconstruction of ancestral sequences, as implemented in CodeML M8, allowed us to infer the ancestral residues 
in the tree root. All of the selected sites, with the exception of site 447, have retained their ancestral residue in the 
larger fraction of the analysed species (Fig. 3b). A relatively low number of substitutions was observed for sites 
395 and 471, while sites 357, 368, 447, 449, 715 and 716 had a higher frequency of amino acid changes. In sites 
368, 395, 447, 449 and 716, hydrophobic ancestral residues were found to be changed mostly to a hydrophilic 
or to another hydrophobic amino acid. Sites 357, 471 and 715 had a polar or charged ancestral residue, and we 
detected substitutions to polar, charged or neutral amino acids.
At site 357, determined to be positively selected by all methods, an aromatic Y has been often changed to 
the sulphur-containing C. Site 368 has undergone a V → T change at the branch ancestral to primates, there-
fore affecting H. sapiens. The highest frequency of amino acid substitutions was detected for site 447, where an 
A → T change was observed to affect numerous species, including primates and H. sapiens. Interestingly, after an 
initial change of the hydrophobic, ancestral residue (V or A) to a hydrophilic one (T), further substitutions were 
Figure 2. Orthologues of MIM are found in a wide variety of vertebrate species. The phylogenetic tree 
includes all species where MTSS1 was identified in this study. Branch length is defined as number of nucleotide 
substitutions per codon. Omega values (ω) for branches are shown in gradient colour code (note that despite the 
bright red colour, the highest values of ω are still less than 0.6). See Supplementary Fig. S2 for node labels and 
Table S3 for exact ω values for branches.
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observed at sites 368, 447 and 449. For example, several primate species have had site 368 reverting from T to a 
non-polar amino acid. The polar ancestral residue at site 471 (T) has been occasionally substituted by another 
polar or non-polar amino acid, while the polar Q at site 715 has been changed to either a basic or a neutral 
residue.
Overall, our evolutionary analysis explains the high degree of conservation in MIM because of broad and 
strong purifying selection. The positively selected sites raise the question of their role in the function of MIM and 
the adaptation of the regions they are found in. However, the scarcity of positively selected sites further supports a 
role for MIM as an essential gene that is strictly required to maintain its functions throughout evolution.
Figure 3. Selection, acting across numerous branches, has affected key sites in several regions of MIM.  
(a) Evolutionarily selected sites (mammals) plotted onto MIM (H. sapiens) protein topology. Methods used are 
indicated on top of their corresponding Y-axes: MEME score in red (p+: mixture distribution weight allocated 
to β+), CodeML in purple (postmean ω: the ratio of dN/dS), SLAC in blue (dN-dS scaled by the length of 
the tested branches) and FUBAR in light blue (mean posterior β-α). “+” Signs denote a residue inferred to 
be under positive selection by more than one method: Y357 (all methods), T471 (MEME and FUBAR). See 
Supplementary Tables S5–S8 for details and exact values. (b) Amino acid substitutions at each selected site plotted 
onto the species tree (mammals). The corresponding residue in H. sapiens is shown next to its branch (top of the 
tree). The ancestral residue, inferred by CodeML, is pinned at the root of the tree. Residue substitutions and 
affected branches are indicated in amino acid colour code. See tree from Fig. 2 for species names (mammals).
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the intra-molecular functional co-dependence between sites converges in the regions with the 
lowest concentration of pathogenic polymorphisms. While we only detected a few positively selected 
residues in MIM, we took another approach to obtain information about the functional regions and their poten-
tial co-operation. We investigated the intra-molecular co-evolution between residues, using MISTIC60 (Fig. 4a). 
Strong co-dependence was observed between amino acids of the Pro-rich region, the middle of the Ser-rich 
region, and its adjacent small hydrophilic patch and small Ser/Thr region. Surprisingly, these regions also showed 
a specific distribution of single nucleotide polymorphisms (SNPs) (see below). The residues showing highest 
co-dependence often clustered outside or next to SH3int motifs. From the I-BAR domain, only four residues 
showed high co-dependence and, interestingly, they were found to be co-evolving with several sites in different 
parts of MIM. Notably, three of these four amino acids belong to the highly variable region encoded by exon 7, 
mentioned above. Considering the domains and regions of MIM individually, strong co-evolution between res-
idues of the same region was only observed within the Pro-rich region, whereas all other major linkages were 
found in between different domains.
Figure 4. Intra-molecular co-dependence, polymorphisms and cancer mutations. (a) Intra-molecular co-
evolution between regions of MIM. Mutual information (MI) values, an estimate of the extent of the mutual 
co-evolutionary relationship between two positions, were plotted onto the protein topology of MIM in a 
Chord diagram. Lines connect pairs of positions with MI >6.5, where red represents the top 5%, black denotes 
70–95% and grey account for the lowest 70%. Domains, regions and motifs of MIM are indicated on the circular 
view of the protein topology. Three regions (333–412, 430–454, 631–728) referred in “d” are indicated. (b) Non-
pathogenic and pathogenic polymorphisms. Each dot represents an amino acid change, plotted onto the protein 
topology of MIM, according to its PolyPhen score, reported by the 1000 Genomes project at Ensembl. Orange: 
PolyPhen >0.45 (possibly/probably damaging, pathogenic), where 0.9 denotes the border between possibly 
(0.45–0.9) and probably damaging (0.9–1). Green: PolyPhen <0.45 (benign, non-pathogenic). Position of 
rs3829037, the only missense polymorphism with MAF >0.05, is pinpointed. See Fig. 1 for protein topology 
code. (c) Mutations found in cancer samples. Like in “b”, each dot represents an amino acid change, plotted over 
the protein topology of MIM, according to its PolyPhen score, calculated by Variant Effect Predictor (VEP). 
Amino acid changes identical to SNPs from the 1000 Genomes project are shown in the same colour code as 
in “b”. Missense mutations, unique to cancer samples are shown in purple: PolyPhen >0.45 (possibly/probably 
damaging, pathogenic), where 0.9 denotes the border between possibly (0.45–0.9) and probably damaging 
(0.9–1). Blue: PolyPhen <0.45 (benign, non-pathogenic). The number (No.) of different cancers where a site was 
found mutated is plotted as a red bar above or below (depending on its PolyPhen score) its corresponding dot. 
The actual number value is indicated at few sites as an example. Analogously, positions of truncating mutations 
are shown within the protein topology scheme of MIM. (d) Ratio of benign versus damaging SNPs throughout the 
full MIM sequence and sub-regions with high MI scores. Amino acid positions indicate: the overall ratio for the 
whole molecule (1–759) and the ratios for regions 333–412 (the second half of the SR region), 430–454 (the small 
central hydrophilic and S/TR region) and 631–728 (the larger part of the PR region). See “a” for region details and 
clusters of residues with high MI scores.
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While MIM has been recurrently linked to various cancers, no disease-specific mutations have been identified 
to date in the MTSS1 gene. However, SNPs also provide insights into possible amino acid variation in humans 
and variation tolerability through the different regions of the protein. So, we next systematically examined the 
exonic SNPs throughout the MIM gene MTSS1, focusing on SNPs resulting in non-synonymous codon substi-
tutions, using data from the 1000 Genomes project61. Plotting their PolyPhen62 scores onto the protein topology 
of MIM, allowed us to examine the distribution of “non-pathogenic” and “pathogenic” (denoted as “benign” and 
“possibly/probably damaging” by PolyPhen) (Fig. 4b). Overall, the “non-pathogenic” amino acid changes were 
considerably fewer (~38%) than the “pathogenic” ones (~62%). However, this ratio dramatically changed when 
individual regions were considered. While the I-BAR domain, Ser-rich region, Leu-rich region and the WH2 
domain all showed a very high frequency of pathogenic polymorphisms, the latter half of the Ser-rich region, 
the minor central regions (hydrophilic and Ser/Thr rich), and the large Pro-rich region had a particularly high 
frequency of non-pathogenic polymorphisms. Interestingly, these regions seemed to notably overlap with the 
regions indicated with strongest intra-molecular co-dependence during evolution (Fig. 4a,d). The low number of 
pathogenic SNPs in the regions of high evolutionary co-dependence further implies physiological importance of 
these potential regulatory regions.
The only missense polymorphism found with a global MAF > 0.05 (minor allele frequency) was rs3829037 
(MAF = 0.162), making it a candidate for a derived allele (DA). Lowest frequency of this DA was found within 
Peruvian population (MAF < 0.01) and the highest in Finnish population (MAF = 0.318). In the MIM pro-
tein, rs3829037 yields a T → A amino acid substitution at position 729, situated exactly between the Pro-rich 
region and the WH2 domain. In addition, this SNP falls in an intronic sequence of a MTSS1-neighbouring gene 
NDUFB9 and is in Linkage Disequilibrium (LD) with rs10195 (r2 = 0.827, D′ = 1) from NDUFB9 in East Asian 
and Esan (Nigeria) sub-populations. No clinical phenotypes have been associated with rs3829037 in MIM, how-
ever, rs10195 from NDUFB9 has been associated with mitochondrial complex I deficiency63.
As MIM has been implicated in various cancers we further went on to analyse what mutations have been 
found in MTSS1 in different cancer samples using cBioPortal64,65. The overall distribution of potentially patho-
genic and non-pathogenic amino acid changes was similar to that from the 1000 Genomes project with mostly 
pathogenic mutations scattered throughout the transcript (Fig. 4c). Importantly, clearly reduced rates of path-
ogenic mutations were again seen in the regions also characterised with high functional co-dependence. Clear 
hotspots for mutations in cancer were not observed as the mutations were spread throughout the coding region, 
with a local enrichment in the first half of the Ser-rich region. The two most frequent individual mutations were 
located close to the first NES and at the start of the Pro-rich region (detected in 4 and 5 different cancer types, 
respectively). Truncating mutations appeared to be concentrated in the I-BAR domain and, especially, at the 
position right after the NLS (detected in 7 cancers).
The heterogeneous pattern of the expression level changes of MTSS1 in chronic lymphocytic 
leukaemia. Our searches on cBioPortal, which contains over 200 deep-sequenced cancer datasets, also 
revealed that MTSS1 is altered in 6% of sequenced cancer patients (altered in 2983 of 49651 sequenced cases/
patients). Interestingly, a clear majority of these alterations were amplifications, although in the literature MIM 
has been mainly considered as a metastatic suppressor, typically characterised with reduced expression in metas-
tasis or primary tumours. Intrigued by this high rate of amplifications, we next revisited the expression levels of 
MTSS1 in different cancers and their matched control tissues by mining the TCGA and GTEx databases using 
GEPIA web tool66. Indeed, as also suggested by accumulating evidence in the literature1,11–17,23–25, expression of 
MTSS1 is differentially regulated in various solid tumours collected in the TCGA database. While the expression 
of MTSS1 is significantly reduced in melanoma, testicular, lung and ovarian cancers, the levels are higher in cer-
tain cancer types of brain and kidney tissues, for example (Fig. 5a,b).
In normal tissues, the expression levels of MIM vary strongly dependent on the tissue. One of the tissues 
showing the highest expression of MIM is spleen5, which is rich in B and T lymphocytes. For this reason, we 
were interested to investigate the expression levels of MTSS1 in blood cancers, especially of B and T cell origin. 
Oncomine67 portal was used to search for the expression levels of MTSS1 in lymphomas and leukaemias. While 
the highest levels of MTSS1 were found in hairy cell and mantle cell lymphomas (Fig. 5c), expression of MTSS1 
was also increased in CLL as compared to normal B cells and highest among different types of leukaemia, with 
the fold changes from normal peripheral blood mononuclear cells (PBMCs) ranging from 1.3–3.8 for different 
microarray probe sets (Fig. 5c,d). When MTSS1 expression in CLL was examined at patient level, in Oncomine, 
strong heterogeneity was detected, with expression levels ranging from levels lower than healthy B-lymphocytes 
to log2 values of four (data not shown).
Several clinical and biological prognostic markers, such as the Rai and Binet staging systems, immunoglobulin 
VH gene mutational status, CD38 and ZAP70 expression, and cytogenetic abnormalities like Del 13q14, Del 17p, 
and Del 11q, can be used to predict the survival outcome and direct treatment strategies for CLL patients68. Based 
on those parameters, CLL patients can be divided in good or poor prognosis patients. Using the dataset of 17 CLL 
patients, selected based on clinical (RAI, Binet staging and prognosis) and biological parameters (IgHV muta-
tional status, CD38 and ZAP70 expression), we went on to measure the levels of MTSS1 transcript by real-time 
PCR in these patient samples. Our sample set contained 10 patients with good prognosis and 7 with poor progno-
sis. Interestingly, despite of overall increased expression, we found that MTSS1 expression was significantly lower 
specifically in samples with poor prognosis as compared to samples with good prognosis (p = 0.0416).
transcriptional regulation of MIM is highly conserved with previously identified as well as 
newly identified transcription factors. Despite the frequently observed alterations in the expression 
levels of MTSS1 in different tissues and various cancers12–16, the mechanisms underlying the changes in expres-
sion are not well understood. We decided to examine the transcriptional regulation of MTSS1 with the aim to 
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Figure 5. MTSS1 expression levels in various cancers and prognostic value in CLL. (a,b) Solid cancers where 
MTSS1 expression is either (a) upregulated or (b) downregulated in comparison with matched control samples.  
Cut-off values: Log2FC = 1, *p < 0.001. (c) MTSS1 expression levels in normal and malignant B cells. CLL (blue) 
and control samples (pale blue) are indicated. Number of samples for each tissue type is shown in the parentheses 
following its name. Analysis statistics: CLL vs. control samples (all normal B cell types shown), Fold change, 
3.658; P-value, 4.69E-07. (d) MTSS1 expression levels in various leukaemias. CLL (blue) and control sample 
(PBMC, pale blue) are indicated. Analysis statistics: CLL vs. PBMC, fold change, 3.843; P-value, 3.99E-77.  
(e) MTSS1 expression is downregulated in CLL patient samples associated with poor prognosis as compared to 
patients with good prognosis. *P-value, 0.0416.
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obtain an overview of its conservation across species. We considered the transcription factors (TF) reported at 
ENCODE69 within a 20 kb genomic region around MTSS1 transcriptional start (10 kb downstream and 10 kb 
upstream)70 (Fig. 6a). The region of interest contained the promoter region marked by H3K4Me3 enrichment 
and putative enhancer regions close to the transcription start site, marked by H3K4Me1. ENCODE data reveal 
numerous TF within this region with total of 38 unique TF and 84 TF binding sites (TFBS) (Supplementary 
Tables S9 and S10), most of which overlap with regions marked either as promoters or as enhancers. We went on 
to investigate the conservation of the TFBS in MTSS1 genes across selected mammals using the MAST tool from 
the MEME suite and position frequency matrices (PFMs) obtained from JASPAR71 and HOCOMOCO72 data-
bases. For most of the TF reported for human MTSS1, we successfully detected their TFBS in the species analysed, 
illustrating high conservation (Fig. 6b).
Next, we searched for novel TFBS in the region upstream of the MTSS1 gene. Enrichment for histone mod-
ification marks from seven cell lines from the ENCODE dataset suggests enhancer activity approximately 10 kb 
from the transcription start site (see the H3K4Me1 track in Fig. 6a). Our search for potential TFBS, using MEME, 
TomTom and MAST tools from the MEME suite73 (not to be confused with MEME from HyPhy, see “Materials 
and Methods” for details) predicted TFBS for four unreported TF within this region. These are, as described at 
GeneCards74, the oncogenic EWSR1-FLI1 fusion TF, the neuronal NEUROG2, the cell proliferation/apoptosis 
regulators SRF and Sox17, implicated in embryonic development. These putative TFBSs were predicted also in 
most of the other species included in the analysis (Fig. 6b). As this region lies further upstream from the promoter 
region of the MTSS1 gene (based on H3K4Me3 enrichment) and is enriched for H3K4Me1 marks, it may have a 
conserved function of recruiting enhancers via TF binding. Overall our analyses imply that transcriptional regu-
lation of the MTSS1 gene is highly conserved within mammals.
Figure 6. Transcription factor binding sequences conservation. (a) Transcription factors reported for human 
MTSS1 at ENCODE. The genomic region where a TF has been identified is shown as a filled box. Regions of TF 
for which we were unable to retrieve a position frequency matrix (PFM) are shown in grey. The region where 
we searched for new, unreported TF, is shown in red and is labelled “SEARCH”. The MTSS1 gene, PhyloP 
conservation score of 100 vertebrate genomes, histone markers (H3K4Me3, H3K27Ac, H3K4Me1) and DNase 
signal are indicated. (b) Detection of the TFBS for the TF reported for MTSS1 for human in 16 other mammalian 
species. If a TFBS was detected, it is indicated for the corresponding species by a check mark. New, unreported 
TF predicted by us for region “SEARCH” are shown in red.
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Discussion
As a protein associated with several cancer types, MIM has attracted a fair amount of research aiming to under-
stand its modes of action. Indeed, interesting biological functions, including plasma membrane and cellular 
cytoskeleton organization and a role in hedgehog signalling and primary cilia, have been attributed to MIM1,3,75. 
However, the physiological role of the protein and, particularly, the seemingly bipartite role it serves in cancers 
still remain largely enigmatic. In an attempt to understand more about MIM and open new avenues to under-
stand its function, we took an in silico approach. By conducting a thorough characterisation of the MIM pro-
tein sequence, we could suggest several regions with new functional properties or sites for protein interactions. 
We found orthologues of MTSS1 in over 90 species and determined its selection during evolution that revealed 
remarkable conservation across species, while at the same time we identified a distinct set of positively selected 
sites. We also analysed the SNPs and cancer-associated mutations of MIM and compared them to the different 
functional regions. Interestingly, we observed an apparent correlation between low numbers of pathogenic SNPs 
and high degree for intra-molecular co-evolution. Finally, we examined the evolutionary conservation of MTSS1 
transcriptional regulation and predicted several new, conserved TFBS.
Across all analysed species, MTSS1 has been subjected to a notable overall negative selection, with branch 
ω-values like those typically observed for housekeeping and essential genes30. Further supporting this notion, 
MTSS1 has been listed amongst the housekeeping genes for human76. The negative selection, likely a response 
to strict functional constraints on MIM, has yielded a high degree of conservation of the molecule, not only 
at sequence level, but also at the domain organization. When comparing MIM from representative species of 
mammals, birds, reptiles and fish, its protein topology is strikingly similar. Therefore, preserving its domains and 
motifs has presumably been crucial for the functions of MIM, as the protein has indeed been implicated in a vari-
ety of processes in different cell types. There are two independent MIM-deficient mouse models published. Both 
of them are viable but develop health problems upon ageing17,26. Considering the high level of conservation of 
the gene, the lack of an overt phenotype at young age is somewhat surprising and might point towards particular 
physiological functions that require more specific conditions to manifest in the mouse models.
The protein topology of MIM is illustrative of its position at the interface between membrane modulation, 
actin cytoskeleton and cellular signalling. Interestingly, our analyses suggested several, so far unreported, features 
of MIM with a presumed functional and structural significance. An interaction of MIM with the AP complex was 
suggested by the identification of four separate conserved binding motifs for the AP µ-subunit. By examining the 
I-BAR structure, we found the first putative APµ-binding site to reside well-exposed, creating a distinct hydro-
phobic patch. We found this encouraging as such hydrophobic regions often mark protein-protein interaction 
sites77. Also, since this complex mediates vesicle endocytosis45, an interplay between AP and the function of 
MIM in actin cytoskeleton and membrane-remodelling appears very plausible. This interaction and its functional 
consequences should be experimentally verified in future studies. We also identified a special amphipathic helix, 
C-helix, found also in some other actin regulatory proteins. C-helix has been shown to bind to GTPase-binding 
domain, Arp2/3 actin nucleator and/or monomeric actin50,51 and, thus, could well contribute to the regulation of 
the cytoskeleton by MIM.
While there is a number of reports that demonstrate MIM protein interactions using truncated versions of 
the protein, the available literature with experimentally validated short linear motifs is scarce, leaving most of 
the motifs annotated by ELM (Supplementary Table S1) to be experimentally validated by future experiments. 
The functional significance of the DSG(XX)S degron motif in SCF-βTRCP-mediated degradation of MIM 
has been previously shown in a manner dependent on the counteracting activity of casein kinase I delta and 
PTEN40,78. Multiple phosphorylation sites for casein kinase I were also annotated by ELM, including CKI site 
at positions 323–329 that overlaps with the degron motif. Various SH3-interacting sites were also annotated. 
Functionality of at least some of them is supported by the demonstration that the interaction of MIM with the 
SH3 domain of cortactin, and the subsequent enhancement of cortactin-mediated actin polymerisation, depends 
on the Pro-rich region of MIM7. From the long list of annotated short functional motifs, we shortlisted some 
of the most interesting candidates for future studies and suggest potential experimental approaches to vali-
date them (Table 1). In addition to AP interaction sites and the C-helix, we selected phosphorylation motifs of 
centrosome-associated Polo-like kinases 1 and 4 as well as NEK2 kinase. Several reports suggest that MIM is 
involved in the maintenance of primary cilia and regulation of Hedgehog signalling75,79–81. Polo-like kinases and 
NEK2 are centrosome-associated kinases involved in cilia biogenesis82–85 and, thus, would be interesting candi-
dates to test in MIM-mediated maintenance of cilia or centrosome association.
In addition to the plausible new functional motifs, we identified a central highly hydrophilic region, mostly 
consisting of basic residues that may promote an association with a negatively charged target, and several disor-
dered binding regions (DBR) that typically convey protein-protein interactions by folding upon binding to the 
partner protein77. One of the plausible binding targets of the hydrophilic region could be the plasma membrane 
itself, as its hydrophilic, largely negatively charged surface could efficiently facilitate the localisation of MIM to 
the membrane. The DBRs, in turn, could facilitate association with interacting partners as well as intra-molecular 
interactions within MIM, as interplay between protein disorder and motifs has been shown86. The SH3 bind-
ing motifs of the Pro-rich region could act in concert with DBR in partner recognition and subsequent inter-
action stabilisation. Folding upon binding is also the mechanism of action for the nearby actin-binding WH2 
domain87,88, for which DBR was also identified.
Notably, the hydrophilic region together with the following minor Ser/Thr region, latter half of the large 
Ser-rich region as well as the large Pro-rich region, all possessed low concentration of potentially pathogenic 
SNPs. This could be partially explained by the plasticity of disordered regions allowing for relatively high varia-
tion. A surprising and very interesting observation, however, was that these same regions also showed strongest 
functional intra-molecular co-dependence. Together, these findings point towards a potentially important regu-
latory role of these regions.
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Our phylogenetic analyses suggested that adaptation driven by positive selection has occurred in several reg-
ulatory regions of MIM. Often, a neutral residue has been substituted to a hydrophilic amino acid that is fre-
quently also predicted as a potential phosphorylation target. This raises the possibility that these substitutions 
provided either structural benefits, due to the different biochemical properties of the amino acids or created novel 
phosphorylation sites for protein activity regulation. Determining the functional impact of such sites could help 
us better understand the functions of MIM and is an important aspect for further investigations. In some rare 
cases, a potential phosphorylation target has been changed into a neutral residue. This might have happened due 
to structural adjustments or because the regulatory site was no longer beneficial. The reasons behind the latter 
possibility raise the question of why a phosphorylation site should be abrogated. In other cases, positive selection 
has yielded substitutions between residues of similar biochemical properties. Such adaptation would imply that 
a certain level of “fine tuning” might have been required in this part of the protein, however, dramatic changes 
have been avoided.
The predominant conservation of the TBFS suggests a similar transcriptional regulation for MTSS1 gene 
across species. The predicted new TFBSs point towards a role in cancer as well as embryonic and neuronal devel-
opment. The overlapping enhancer activity adds another layer of regulation to MIM. Overall, this analysis sug-
gests a solid starting point for further investigations on the transcriptional regulation of MTSS1.
In cancer, MIM has typically been reported being downregulated, however, with some exceptions of the oppo-
site findings1,23–25. Here, we mined protein expression databases TCGA and GTEx to gain a broader view on the 
MTSS1 gene expression levels of MIM in different cancers. We found, somewhat surprisingly, that increased 
expression of MTSS1 seems to be a relatively common feature of primary tumours (Fig. 5). Among different leu-
kaemia, CLL showed particularly high levels of MTSS1. Our real-time PCR analysis from different CLL patient 
samples showed, interestingly, that the patient samples with poor prognosis and increased organ infiltration (con-
firmed by RAI staging) expressed significantly lower levels of MTSS1 as compared to samples of good prognosis. 
Of note, CLL cells accumulate and proliferate in the lymphoid tissues and in advanced stages can undergo an 
aggressive transition to the so-called Richter’s syndrome and become a high-grade lymphoma39. Thus, we could 
speculate that the heterogeneous expression pattern of MTSS1 in CLL could reflect a different propensity to 
accumulate in the tissues and eventually transform in a more aggressive disease. This could be reminiscent of the 
notion that in the head and neck squamous carcinoma, primary tumours show high expression of MTSS1 but its 
downregulation promotes metastases23. These findings makes those cancers good candidates for further exami-
nation on the role of MIM in their aggressive transformations.
Materials and Methods
A graphical overview of the computational workflow is presented in Supplementary Fig. S1, following the order 
of the sections below.
Motif type Sequence and motif (ELM) Proposed experimental approaches
Dynamics of cellular membranes
Tyrosine-based sorting signal 
responsible for the interaction with 
mu subunit of AP (Adaptor Protein) 
complex.
177 YLLL 180 | TRG_ENDOCYTIC_2
530 YDYF 533 | TRG_ENDOCYTIC_2
532 YFSV 535 | TRG_ENDOCYTIC_2
562 YRRM 565 | TRG_ENDOCYTIC_2
- Co-immunoprecipitation of MIM and AP complex 
in cells where endocytosis is stimulated by different 
pathways.
- Immunofluorescence
- Proximity ligation assay
Canonical LC3-interacting (LIR) 
motif that binds to Atg8 protein 
family members to mediate processes 
involved in autophagy.
175 DKYLLL 180 | LIG_LIR_Gen_1
- Co-immunoprecipitation of MIM and regulator of 
autophagy
- Immunofluorescence
- Proximity ligation assay
Actin cytoskeleton
Amphipathic alpha helix (“C-helix”) 
that binds the GTPase-binding domain 
(GBD) in WASP and N-WASP.
487 LALALSRGL 495 | LIG_GBD_
Chelix_1
- In vitro actin polymerization assay using pyrene 
actin.
- Pull-down assays using GTPase-binding domain 
(GBD) of WASP or related proteins.
Centrosome-associated kinases
Ser/Thr residue phosphorylated by 
the Plk1
7 KECSALG 13 | MOD_Plk_1
212 EEISMLG 218 | MOD_Plk_1
218 GEITHLQ 224 | MOD_Plk_1
254 SDYSWSY 260 | MOD_Plk_1
519 SEDTIPS 525 | MOD_Plk_1
- Detection of phosphorylation by mass 
spectrometry, possibly combined to functional 
inhibition of the kinase in question.
- In vitro kinase assays.
Ser/Thr residue phosphorylated by 
Plk4
44 LRTTVVA 50 | MOD_Plk_4
198 RFCTFIS 204 | MOD_Plk_4
NEK2 phosphorylation motif with 
preferred Phe, Leu or Met in the 
−3 position to compensate for less 
favorable residues in the +1 and +2 
position.
23 MKGSYP 28 | MOD_NEK2_1
44 LRTTVV 49 | MOD_NEK2_1
485 LALSRG 490 | MOD_NEK2_1
503 LQCSSG 508 | MOD_NEK2_1
546 FDKSST 551 | MOD_NEK2_1
745 LKKTTT 750 | MOD_NEK2_1
NEK2 phosphorylation motif with 
specific set of residues in the +1 and 
+2 position to compensate for less 
favorable residues in the −3 position.
589 GVATIR 594 | MOD_NEK2_2
Table 1. Selected functional motifs proposed for experimental validation.
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Identification of orthologues. MTSS1 transcript variant 1 from human (RefSeq: NM_001282971.1) and 
mouse (RefSeq: NM_144800.2) were used to identify orthologous transcripts in G. gallus (chicken), A. carolinen-
sis (green anole lizard) and L. oculatus (spotted gar) from the NCBI database (National Center for Biotechnology 
Information, https://www.ncbi.nlm.nih.gov/). Translated MIM sequences from human, chicken (RefSeq: 
XM_015283097.1), lizard (RefSeq: XM_016992753.1) and spotted gar (RefSeq: XM_015357664.1) were then used 
in TBLASTN searches at NCBI against mammalian, avian, reptilian and fish databases, respectively. To assess 
that the identified orthologues (Supplementary Table S2) correspond to isoform 1 from human (and mouse), we 
considered the BLAST similarity scores and the exon/intron organisation. For example, exon 7 is alternatively 
spliced in the human MTSS1 transcript variant 2 (RefSeq: NM_014751.5, UniProt: O43312, see next section) 
so we expected the real orthologues to have the exon 7 like in the human transcript variant 1. In case a detailed 
comparison between orthologues was required, we used SIM (alignment tool for protein sequences, https://web.
expasy.org/sim/) and inspected the results in LalnView89. As a final verification, we performed reciprocal BLAST 
hit searches for each sequence against human and obtained a match to MTSS1 isoform 1.
protein sequence characterisation. MIM domains were predicted by SMART90 (Simple Modular 
Architecture Research Tool, http://smart.embl-heidelberg.de/) in “normal mode” with the option to consider 
Pfam domains. Short functional motifs were searched at ELM44 (Eukaryotic Linear Motif, http://elm.eu.org/), by 
MIM UniProt Identifier (such as “MTSS1_HUMAN O43312”) to retrieve the conservation scores (cs)91 of the 
motifs. Motif coordinates following isoform 1 of MIM, with cs >0.6 (motif is present in over 60% of all homol-
ogous sequences at UniRef90) are listed in Supplementary Table S1. We assume that our chosen cut-off values 
are biologically reasonable, as for example the experimentally validated DSG(XX)S degron motif is identified by 
ELM as DEG_SCF_TRCP1_1 with p-value = 1.264E-04 and cs = 0.710. For regions where positively selected sites 
were identified (see “Molecular Evolution Study” below), we used the NetPhos92 tool (http://www.cbs.dtu.dk/
services/NetPhos/) at CBS (Center for Biological Sequences analyses) to conduct a more broad search for poten-
tial phosphorylation regions. Like ELM, NetPhos was also able to spot sites that are experimentally validated 
for MIM, such as Y397 and Y39841, which were detected even slightly below the threshold. Disordered binding 
regions (DBR) were predicted at IUPred2A42 (https://iupred2a.elte.hu/) and regions with IUPred and ANCHOR 
scores greater than 0.8 were indicated onto MIM. Primary and secondary structure features were observed by SA 
(Sequence Analysis v1.7.2, http://informagen.com/SA/) and tools from EMBOSS93 (European Molecular Biology 
Open Software Suite, v6.6.0). Coordinates defining protein topology were listed in JSON syntax and submitted to 
the Pfam custom domain generator (http://pfam.xfam.org/generate_graphic/).
sequence alignment. We created multiple sequence alignments (MSA) separately for mammalian ortho-
logues, as well as a combined alignment for all species (Supplementary Datasets S1 and S2). Amino acid sequences 
were aligned by PRANK52 (v150803), using guide trees obtained from TimeTree53 (http://www.timetree.org/) and 
using a total of 10 iterations (option ‘−iterate = 10’). Coding DNA sequences (CDS) of orthologues were codon 
aligned by PAL2NAL94 (v14.0), following their protein MSA.
Molecular evolution study. The codon alignments and phylogenetic trees from above were subjected to a 
series of evolutionary selection tests by PAML54 (Phylogenetic Analysis using Maximum Likelihood) and HyPhy59 
(Hypothesis testing using Phylogenies). CodeML from PAML (v4.9 h) was used with ModelFree (free ratios: 
independent ω for each branch) for all species. Omega values for branches, estimated by CodeML were rendered 
in colour-code onto the tree by PhyTools95 package for R (https://www.r-project.org/). Branches with omega 
>0.15 are listed in Supplementary Table S3 and node labels are found in Supplementary Fig. S2. For mammals, 
CodeML nested models M7 versus M8, and M8A versus M8, were used. Model pairs were compared (2ΔL) in 
Gnumeric (http://www.gnumeric.org/) and the chidist formula (survival function of the χ2 distribution) was used 
to calculate the likelihood estimate (p-value) for rejecting the null hypothesis (Supplementary Table S4). Both 
neutral models (M7 and M8A) were rejected in favour of the model for positive selection (M8). Sites determined 
to be under positive selection by Bayes Empirical Bayes (BEB) with posterior probability (PP) higher than 0.9 
were considered (BEB PP > 0.9). In HyPhy (v2.3.14) we used the methods SLAC56 (Single-Likelihood Ancestor 
Counting), FUBAR57 (Fast Unconstrained Bayesian AppRoximation) and MEME58 (Mixed Effects Model of 
Evolution). For SLAC, sites determined to be under negative or positive selection with p < 0.05 were considered. 
For FUBAR, we considered sites determined to be under negative or positive selection with Bayesian PP > 0.9. 
For MEME, sites determined to be under episodic (diversifying) selection with p < 0.05 were considered. More 
information on the positively selected sites (including SLAC and MEME results with the default p < 0.1) can 
be found in Supplementary Tables S5–S8.
In our ModelFree run, we encountered a technical problem: the data acquired by CodeML reported abnor-
mally high omega values for three branches: 97..100 (ancestral to S. salar and E. lucius) with ω = 551.9418, 
118..119 (ancestral to P. humilis, P. major, S. vulgaris and F. albicollis) with ω = 203.0243 and 178..11 (M. neme-
strina) with ω = 999.0000 (species tree with node labels is shown in Supplementary Fig. S2). The branches had 
dS = 0.0000, which resulted in the abnormal estimation of ω, therefore, we excluded these ω values from Fig. 2 
(branches coloured in black).
Co-evolutionary analyses. Intra-molecular co-dependence between amino acids was determined by 
MISTIC60 (Mutual Information Server to Infer Coevolution, (http://mistic.leloir.org.ar/, accessed August 2017). 
We used MSA of all mammalian species (Supplementary Dataset S2), as described at the “Sequence alignment” 
step. Circular representation of MIM protein topology was rendered in GIMP (https://www.gimp.org/).
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structural analyses. Conservation of the 3D structure of the I-BAR domain was estimated at the ConSurf47 
server (http://consurf.tau.ac.il/), using an MSA of MIM from all species (Supplementary Dataset S1). Crystal 
structure of the I-BAR domain (PDB: 2D1L)48 from M. musculus was visualised and exported by UCSF Chimera96.
Distribution of sNps and mutations in cancer. The 1000 Genomes project61 data at Ensembl (GRCh38.
p12, Ensembl 93: Jul 2018) was searched for missense SNPs of MTSS1 isoform 1 (ENST00000325064.9). In our 
searches, PolyPhen-262 (HumVar) automatically classified SNPs with low to medium scores (0–0.444) as “benign”, 
those with medium to high scores (0.453–0.906) as “possibly damaging”, and those with the highest scores (0.909–1) 
as “probably damaging”.
The cBioPortal64,65 for Cancer Genomics (http://www.cbioportal.org/, accessed August 2018) was used to 
search for mutations in MIM identified in different cancers. To obtain PolyPhen-2 (HumVar) scores for these 
mutations, we submitted their genomic coordinates (GRCh37) to Ensembl Variant Effect Predictor (https://
www.ensembl.org/Tools/VEP). Similarly to the scores for SNPs, PolyPhen-2 classified the mutations as “benign” 
(0–0.445), “possibly damaging” (0.485–0.905) and “probably damaging” (0.91–1).
The PolyPhen-2 scores were plotted in Gnumeric onto the protein topology of MIM, where we chose 0.45 as 
the borderline value to distinguish between benign and possibly/probably damaging SNPs or mutations found 
in cancer.
Cancer expression databases and web tools. Expression data and plots for solid cancers were retrieved 
from TCGA (https://cancergenome.nih.gov, cancer studies, matched control samples) and GTEx (https://gtex-
portal.org/home, normal control samples data) databases using GEPIA66 web tool (http://gepia.cancer-pku.cn) 
with following cut-off values: Log2FC (fold change) = 1, *p < 0.001, accessed in August of 2018. Expression 
data in lymphomas/leukaemias and corresponding plots were retrieved using Oncomine67 portal (https://www.
oncomine.org/, Thermo Fisher Scientific), accessed in August of 2018. Oncomine platform filters correspond-
ing to Fig. 5: Gene: MTSS1, Analysis Type: Cancer vs Normal Analysis, Cancer Type: Chronic Lymphocytic 
Leukemia. Dataset tab: Basso lymphoma97 (Fig. 5c) or Heferlach leukaemia98 (Fig. 5d) with default dataset thresh-
old values. Dataset visualization tab: grouped by: Cancer and Normal Type, Show: All Samples in Dataset.
Differential analysis in GEPIA is done by one-way ANOVA, using disease state (Tumour or Normal) as varia-
ble for calculating differential expression. Oncomine returns fold change as the difference in the means of the two 
groups being compared and t-test is applied.
Human ethics statement. CLL patients were diagnosed according to the updated National Cancer 
Institute Working Group (NCIWG) guidelines99. Peripheral blood samples were obtained after patients’ informed 
consent (written), as approved by the institutional ethics committee of San Raffaele University Hospital (Milano, 
Italy). The study has been specifically approved by the OSR ethics committee in the protocol VIVI-CLL titled:”In 
vivo and in vitro characterisation on CLL”. All methods were performed in accordance with the relevant guidelines 
and regulations.
Human primary sample purification. Leukemic lymphocytes were obtained from peripheral blood of 
CLL patients, diagnosed according to the updated National Cancer Institute Working Group (NCIWG) guide-
lines99. All patients were either untreated or off therapy for at least 6 months before the beginning of the study. 
Leukemic CD19 cells were negatively selected from fresh peripheral blood using RosetteSep B-lymphocyte 
enrichment kit (StemCell Technologies). Purity of all preparations was always more than 99%, and the cells 
co-expressed CD19 and CD5 on their cell surfaces as checked by flow cytometry (FC500; Beckman Coulter); 
preparations were virtually devoid of natural killer (NK) cells, T lymphocytes, and monocytes. Patients have been 
divided in GOOD prognosis and POOR prognosis based on clinical and biological parameters.
Rt-qpCR. RNA was isolated from both cell lines and primary samples with ReliaPrep RNA Cell mini Prep 
System (Promega) according to the manufacturer’s instructions. cDNA was synthesized according to the manu-
facturer’s protocol using Maxima RevertAid H minus First Strand cDNA Synthesis Kit reagents (Thermo Fisher 
scientific). qRT-PCR analysis was performed using an ABI7900 Thermal Cycler instrument (Applied Biosystem) 
for human MTSS1 (NM_001282974.1, NM_014751.5, NM_001282971.1) with the SYBR GREEN system using 
following primers: CATCATCAGCGACATGAAGG (forward) and CACATCCTGGTGAGAGCAGA (reverse). 
GAPDH was used as a reference gene and delta Ct values were analyzed by two-tailed t-test with Welch correc-
tion. Data presented as 2(−δ Ct).
transcription factor binding sequences. A 20 kb region (chr8:124717884–124737884, GRCh38/
hg38), defined as ±10 kb from the transcription start site of MTSS1 gene (relative to transcript variant 1, RefSeq 
NM_001282971.1 or Gencode ENST00000325064.9) was searched for evidence of TFBSs. The coordinates of 
the short genomic regions, where transcription factors are reported at ENCODE69 (v3, GRCh37/hg19, https://
www.encodeproject.org/) were obtained (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/encodeDCC/
wgEncodeRegTfbsClustered/ from file “wgEncodeRegTfbsClusteredV3.bed”) and used at the UCSC Genome 
Browser. Genomic coordinates corresponding to the GRCh38/hg38 human genome assembly were identified 
(Supplementary Table S9) by the LiftOver tool (http://genome.ucsc.edu/cgi-bin/hgLiftOver). Similarly, their 
coordinates in the genomes (Supplementary Table S11) of other species were extracted again by LiftOver. 
Sequences were retrieved by “fastaFromBed” within the BedTools package (http://bedtools.readthedocs.io/) and 
sorted by region.
The TFBS reported for human were searched across species by MAST (Motif Alignment and Search Tool), 
part of the MEME suite73 (v4.12.0) with relaxed cutoff values (−mev 10, −ev 10). We obtained position frequency 
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matrices (PFMs) from JASPAR core 2018 (redundant and non-redundant) and HOCOMOCO v11 (core and full) 
databases71,72. To search for novel TFBS, we selected a genomic region (chr8:124736177–124736777, GRCh38/
hg38, named “SEARCH” in Fig. 6) based on its enrichment for H3K4Me3, H3K27Ac, H3K4Me1 histone marks 
for seven ENCODE cell lines and PhyloP conservation scores for 100 vertebrates at the UCSC Genome Browser 
(Fig. 6). Sequences were collected from different species as described above and processed by a custom shell script 
in a three step MEME suite analysis (see “Software and data”). First, screens for novel motifs were done by MEME 
(Multiple Em for Motif Elicitation), utilising all three distribution options (−oops, −zoops, −anr) in series, as 
well as, allowing the size of the discovered motif to increase by a single nucleotide in the range of 6–24. To avoid 
false-positives, sequences were masked by RepeatMasker (http://www.repeatmasker.org/) and a Markov model 
background profile was generated by “fasta-get-markov” (part of MEME suite). Then, TomTom was used to match 
all identified motifs from all distribution/size combinations against JASPAR core 2018 (non-reduncant) database, 
considering the 9 available function distributions in individual runs. In the third step, PFMs of identified tran-
scription factors were collected and used in a MAST run against the original DNA sequences, with strict settings 
(−mev 0.0001 −ev 0.0001) filtering the best matches. Graphical representation of the MTSS1 gene, genomic 
regulatory elements and TFBS coordinates was rendered by the UCSC Genome Browser.
software and data. All bioinformatics software used for this work was installed on a Slackware (http://
www.slackware.com/) GNU/Linux system, almost exclusively from the scripts available at the SlackBuilds.org 
project (http://slackbuilds.org/). Materials such as custom shell scripts, bed files, sequences, phylogenetic trees 
and raw data are accessible at our GitHub repository (https://github.com/mattilalab/), a link to which is provided 
on our web-site (http://mattilalab.utu.fi/).
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